Skip to main content

Advertisement

Log in

Control of Cancer of the Cervix in Low- and Middle-Income Countries

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Cervical cancer is the fourth most common cancer among women globally but the second most common in Sub-Saharan Africa (SSA). The high burden of cervical cancer in developing countries reflects the absence of cervical cancer prevention programs. The majority of the incident cases and deaths from cervical cancer, greater than 85 %, occur in developing countries, where resources for early detection and treatment are severely limited. Survival from cancer in Africa is very poor due to late presentation and lack of access to effective treatment. Radiation, chemotherapy, and surgical oncology are not available in many parts of SSA. It is estimated that by 2030 cancer will affect much larger numbers of people living in low- and middle-income countries. Very few, if any, are prepared for or have sufficient health care infrastructure to provide acceptable services. It is imperative that governments in low- and middle-income countries pay urgent attention to the problem by developing National Cancer Control Programs, which should include population-based registries and data collection systems that allow an accurate evaluation of the burden of disease and hence resources required to meet it.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr. Accessed 28 Sept 2014.

  2. Miller AB. Cervical cancer screening programmes. Managerial Guidelines. Geneva: World Health Organisation; 1992:24–25.

    Google Scholar 

  3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.

    Article  CAS  PubMed  Google Scholar 

  4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Keertie, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med. 2003;348:518–27.

  5. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11:165–73.

    Article  PubMed  Google Scholar 

  6. Gondos A, Brenner H, Wabinga H, Parking DM. Cancer survival in Kampala, Uganda. Br J Cancer. 2005;92(9):1808–12.

    Article  CAS  Google Scholar 

  7. Independent Evaluation Group Studies. Annual Review of Development Effectiveness: Achieving Sustainable Development. 2009 World Bank.

  8. Hanna T, Kangolle A. Cancer control in developing countries: using health data and health services research to measure and improve access. Quality and efficiency. BMC Int Health Human Rights. 2010;10:24.

    Article  PubMed Central  PubMed  Google Scholar 

  9. World Health Organization, working together for health: the world health report 2006 (Geneva, Switzerland, WHO, 2006).

  10. Scheffler RM, Mahoney CB, Fulton BD, Dal Poz MR, Preker AS. Estimates of Health care professional shortages in Sub-Saharan Africa by 2015. Heath Aff. 2009;28(5):849–62.

  11. UNAIDS, the Joint United Nations Programme. http://www.unaids.org. Accessed 28 Sept 2014.

  12. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1–19.

  13. Weiser TG, Regenbogen SE, Thompson EK, et al. An estimation of the global volume of surgery: a modeling strategy based on available data. Lancet. 2008;372:139–44.

    Article  PubMed  Google Scholar 

  14. Yii Mk, Ng KJ. Risk-adjusted surgical audit with the POSSUM scoring system in a developing country. Br J Surg. 2002;89:110–3.

    Article  Google Scholar 

  15. Ouro-Bang’na Maman AF, Tomta K. Ahuaangbevi S, Chobli M. Deaths associated with anaesthesia in Togo, West Africa. Trop Doct. 2005:35:220–2.

  16. Funk LM, Weiser TG, Berry WR, et al. Global operating theatre distribution and pulse oximetry supply: an estimation from reported Data. Lancet. 2010;376:1055–61.

  17. Wairagala W. Working to improve access to palliative care in Africa. Lancet Oncol. 2010;11:227–8.

    Article  PubMed  Google Scholar 

  18. Yohana E, Kamuhabwa A, Mujinia P. Availability and affordability of anticancer medicines at the Ocean road Cancer Institute in Dar es Salaam, Tanzania. East Afr J Public Health. 2011;8(1):52–7.

    PubMed  Google Scholar 

  19. Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy. World Health Organisation, Geneva, Switzerland; 2012.

  20. De Sanjose S, Quint WGV, Alemany A, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.

    Article  PubMed  Google Scholar 

  21. Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in Sub-Saharan Africa. Int J Cancer. 2013;134(6):1389–98.

    Article  PubMed  Google Scholar 

  22. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;102:1557–67.

    Article  PubMed  Google Scholar 

  23. Sankaranayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.

    Article  Google Scholar 

  24. Kjaer SK, Sigurdsson K, Iversen O, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (tyes 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res. 2009;02(10):868–78.

    Article  Google Scholar 

  25. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. Lancet. 2007;369:2161–70.

    Article  CAS  PubMed  Google Scholar 

  26. Lu B, Kumar A, Castellsague X, Guiliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and disease among women. A systematic review and meta-analysis. BMC Infect Dis. 2011;11:13.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Ladner J, Besson M, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries 2009 and 2013. BMC Public Health. 2014;14:670.

    Article  PubMed Central  PubMed  Google Scholar 

  28. GAVI, the Vaccine Alliance. http://www.gavialliance.org. Accessed 28 Sept 2014.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lynette Denny MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Denny, L. Control of Cancer of the Cervix in Low- and Middle-Income Countries. Ann Surg Oncol 22, 728–733 (2015). https://doi.org/10.1245/s10434-014-4344-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4344-8

Keywords

Navigation